Categories
COVID-19

Gilead’s remdesivir shows benefit in some patients with moderate Covid-19 – MedCity News

Topline results from the company’s Phase III trial showed a statistically significant improvement in the time patients took to recover after getting the drug for five days, but data for the 10-day regimen did not reach statistical significance despite also showing an improvement.

  1. Gilead’s remdesivir shows benefit in some patients with moderate Covid-19 – MedCity News